Cite
Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.
MLA
Lin, YunYu, et al. “Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.” OncoTargets & Therapy, vol. 15, July 2022, pp. 831–36. EBSCOhost, https://doi.org/10.2147/OTT.S372134.
APA
Lin, Y., Lei, Y., Li, L., Su, X., Tian, Q., & Wu, W. (2022). Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report. OncoTargets & Therapy, 15, 831–836. https://doi.org/10.2147/OTT.S372134
Chicago
Lin, YunYu, Yan Lei, LinWei Li, Xiaoxing Su, Qiqi Tian, and Wendy Wu. 2022. “Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report.” OncoTargets & Therapy 15 (July): 831–36. doi:10.2147/OTT.S372134.